GSA Capital Partners’s Pfizer PFE Stock Holding History

GSA Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-161,114	Closed	-$4.01M	–	2060
2025 Q4	$4.01M	Buy	161,114 +124,411	+339%	+$3.14M	0.35%	8
2025 Q3	$935K	Buy	36,703 +22,781	+164%	+$562K	0.08%	444
2025 Q2	$337K	Sell	13,922 -108,114	-89%	-$2.52M	0.02%	1191
2025 Q1	$3.09M	Buy	122,036 +102,148	+514%	+$2.67M	0.28%	10
2024 Q4	$528K	Sell	19,888 -12,898	-39%	-$350K	0.04%	848
2024 Q3	$949K	Buy	32,786 +15,310	+88%	+$447K	0.07%	500
2024 Q2	$489K	Buy	17,476 +1,650	+10%	+$45.4K	0.03%	983
2024 Q1	$439K	Buy	+15,826	New	+$439K	0.03%	966
2022 Q4	–	Sell	-6,712	Closed	-$294K	–	1785
2022 Q3	$294K	Buy	+6,712	New	+$326K	0.04%	946
2022 Q2	–	Sell	-25,510	Closed	-$1.32M	–	1711
2022 Q1	$1.32M	Buy	25,510 +21,806	+589%	+$1.13M	0.18%	92
2021 Q4	$219K	Sell	3,704 -8,106	-69%	-$402K	0.03%	1151
2021 Q3	$508K	Buy	+11,810	New	+$523K	0.05%	684
2021 Q1	–	Sell	-8,257	Closed	-$304K	–	1390
2020 Q4	$304K	Buy	+8,257	New	+$303K	0.05%	725
2020 Q1	–	Sell	-7,167	Closed	-$266K	–	1431
2019 Q4	$266K	Sell	7,167 -6,505	-48%	-$232K	0.03%	1107
2019 Q3	$466K	Buy	+13,672	New	+$497K	0.06%	599
2019 Q2	–	Sell	-17,707	Closed	-$713K	–	1672
2019 Q1	$713K	Sell	17,707 -10,424	-37%	-$417K	0.07%	480
2018 Q4	$1.17M	Sell	28,131 -1,406	-5%	-$58.4K	0.13%	161
2018 Q3	$1.24M	Buy	29,537 +19,084	+183%	+$735K	0.07%	537
2018 Q2	$360K	Buy	+10,453	New	+$357K	0.02%	1310
2018 Q1	–	Sell	-61,769	Closed	-$2.12M	–	1775
2017 Q4	$2.12M	Buy	+61,769	New	+$2.11M	0.13%	213
2017 Q3	–	Sell	-7,116	Closed	-$227K	–	1829
2017 Q2	$227K	Buy	+7,116	New	+$224K	0.01%	1456
2017 Q1	–	Sell	-13,854	Closed	-$427K	–	1935
2016 Q4	$427K	Sell	13,854 -24,132	-64%	-$737K	0.03%	1108
2016 Q3	$1.22M	Sell	37,986 -8,505	-18%	-$284K	0.07%	495
2016 Q2	$1.55M	Sell	46,491 -58,350	-56%	-$1.86M	0.09%	364
2016 Q1	$2.95M	Sell	104,841 -125,391	-54%	-$3.58M	0.19%	70
2015 Q4	$7.05M	Buy	230,232 +178,063	+341%	+$5.6M	0.35%	10
2015 Q3	$1.55M	Sell	52,169 -53,940	-51%	-$1.73M	0.08%	377
2015 Q2	$3.38M	Buy	106,109 +57,344	+118%	+$1.87M	0.13%	131
2015 Q1	$1.61M	Sell	48,765 -2,636	-5%	-$83.8K	0.06%	486
2014 Q4	$1.52M	Sell	51,401 -42,902	-45%	-$1.23M	0.11%	239
2014 Q3	$2.65M	Sell	94,303 -62,347	-40%	-$1.75M	0.14%	145
2014 Q2	$4.41M	Buy	+156,650	New	+$4.47M	0.2%	76
2014 Q1	–	Sell	-230,320	Closed	-$6.69M	–	1750
2013 Q4	$6.69M	Buy	+230,320	New	+$6.7M	0.53%	6
2013 Q3	–	Sell	-90,477	Closed	-$2.4M	–	1635
2013 Q2	$2.4M	Buy	+90,477	New	+$2.5M	0.29%	41

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

GSA Capital Partners's PFE Position: Q1 2026 in Review

GSA Capital Partners sold out of Pfizer (PFE) in Q1 2026, closing a stake of 161,114 shares — an estimated $4.01M sold.

GSA Capital Partners first reported a position in PFE in Q2 2013 and held it in 34 quarters. The position peaked at $7.05M in Q4 2015. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

GSA Capital Partners reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 161,114 Pfizer shares in Q1 2026, an estimated $4.01M.
GSA Capital Partners first reported a position in Pfizer in Q2 2013 and held it in 34 quarters.
GSA Capital Partners's Pfizer position peaked at $7.05M in Q4 2015.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.